Method of treating pleural abnormality
The invention relates to a method of treating pleural abnormalities in a subject in need thereof, comprising the steps of: (a) attaching a biodegradable polymeric membrane onto a pleural wound to elicit fibronectin from fibroblasts to cause fibrous adhesion; and (b) securing the membrane with securement products, including sutures, staples, and sealants. The present invention also relates to a biodegradable adhesion membrane used for treating pleural abnormalities, comprising: a biodegradable base material selected from the group consisting of polycaprolactone (PCL), polylactic acid or polylactide (PLA), polyhydroxybutyrate (PHB), poly(ethylene adipate), poly(butylene adipate) (PBA), chitosan, hyaluronic acid, and polyglycolic acid (PGA); wherein the thickness of the membrane is 0.1-1 mm.
1. A method of treating pleural abnormalities in a subject in need thereof, comprising the steps of:
(a) attaching a biodegradable polymeric membrane onto a pleural wound to elicit fibronectin from fibroblasts to cause fibrous adhesion; and
(b) securing the membrane with securement products, including sutures, staples, and sealants.
2. The method of claim 1 , wherein the pleural abnormalities comprise a pneumothorax and a pleural effusion.
3. The method of claim 1 , wherein the pleural wound includes a parietalis pleural wound and a visceralis pleural wound.
4. The method of claim 1 , wherein the biodegradable polymeric membrane is a non-porous biodegradable polymeric membrane or a porous biodegradable polymeric membrane having a plurality of pores.
5. The method of claim 4 , wherein the diameter of each pore of the porous biodegradable polymeric membrane is 0-500 μm.
6. The method of claim 1 , wherein the biodegradable polymeric membrane is selected from the group consisting of polycaprolactone (PCL), polylactic acid or polylactide (PLA), polyhydroxybutyrate (PHB), poly(ethylene adipate), poly(butylene adipate) (PBA), chitosan, hyaluronic acid, and polyglycolic acid (PGA).
7. The method of claim 6 , wherein the biodegradable polymeric membrane is polycaprolactone (PCL).
8. The method of claim 1 , wherein the length of each side of the biodegradable polymeric membrane is at least 5 mm longer than the corresponding sides of the wound.
9. The method of claim 1 , wherein the surface of the biodegradable polymeric membrane is further coated with fibronectin and/or hydrophilic polymer.
10. The method of claim 1 , wherein the biodegradable polymeric membrane further carries antibiotics, analgesic drug, and/or anticancer drugs.